AbbVie Moves Ahead on Plaque Psoriasis Application and Arthritis Clinical Trial


By Mark Terry

AbbVie has submitted a Biologics License Application (BLA) to the U.S. FDAfor risankizumab, an interleukin-23 (IL-23) inhibitor for plaque psoriasis.

The application is based on data from four Phase III clinical trials: ultIMMA-1, 2, IMMhance and IMMvent. The drug met all co-primary and ranked secondary endpoints with no new safety problems.

The drug was developed in a collaboration with Boehringer Ingelheim.

In the trials, more than 2,000 patients were treated.

“The risankizumab submission represents an important milestone in our goal of advancing treatment for people living with immune-mediated diseases,” said Michael Severino, AbbVie’s executive vice president, research and development and chief scientific officer. “Risankizumab has the potential to be an important treatment option for people living with plaque psoriasis and we look forward to working with the FDA throughout the review process.”

AbbVie also announced positive data from its ongoing Phase IIB/III SELECT-SUNRISE clinical trial. This trial evaluated upadacitinib in Japanese patients for moderate to severe rheumatoid arthritis. The data showed that at 12 weeks, all doses, 7.5mg, 15mg, 30mg, once-daily, met the primary endpoint of ACR20alpha compared to placebo.

“We are encouraged by these data, which show that upadacitinib provides improvements in important measures such as achieving ACR response and clinical remission, in people living with rheumatoid arthritis in Japan,” Severino said in a statement. “SELECT-SUNRISE reflects our continued commitment to offering innovative solutions with the potential to improve the lives of Japanese patients living with this serious, debilitating condition.”

Upadacitinib was discovered and developed by AbbVie. It is an oral drug that inhibits JAK1, which is linked to various immune-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease. In addition to those diseases, the drug is being evaluated for ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

AbbVie will be releasing its first-quarter financials tomorrow. In the last quarter, it reported a 2.78% increase in earnings, which was more than most analysts expected. Generally, the stock has outperformed the industry this year, which may not be saying much. The industry has shown an overall drop of 4.3% and AbbVie’s have decreased 4.1%.

Shares are currently trading for $91.3. The 52-week high was $125.86 and the low was $64.61. Shares opened today at $90.96.

Also today:

PixarBio CEO and 2 Associates Arrested and Charged with Fraud

Stock Dives as Celldex Cuts 20% of Staff After Phase II Breast Cancer Failure

Corvidia Raises $60 Million Series B to Push into the Clinic

Novartis Joins Innovative Solution Trend for Clinical Trials: Launches FocalView App

Amgen’s New Products Deliver Double-Digit Growth While Facing Down Pricing Pressure for New Migraine Drug

Published by


Mark Terry is a freelance writer and editor specializing in biopharma, clinical diagnostics, medical practice management and other life science topics. He holds a degree in microbiology and public health, spent 18 years in clinical genetics, and writes regularly for His work has been published by FierceBiotech, G2 Intelligence, Dark Daily, Medical Economics, Podiatry Management and numerous others.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s